SCHEMBL5483057

SCHEMBL5483057

NS(=O)(=O)N1CSC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294322 0.60
SCHEMBL1036617 0.56
SCHEMBL8273013 0.49
SCHEMBL4141702 0.49
SCHEMBL11688163 0.49 CA1 (0.69)
SCHEMBL1920577 0.48
SCHEMBL2723676 0.46
SCHEMBL391423 0.46
Hydrochloric Acid SCHEMBL29819829 0.44 CA1 (0.88)
SCHEMBL21356989 0.44 CA1 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104903320-B Nitrogen-containing heterocycle compound or its salt 富士胶片株式会社 2018-11-13 CN disclosed
CN-106019830-A Resist composition and method for producing resist pattern 住友化学株式会社 2016-10-12 CN disclosed
CN-104903320-A Nitrogen-containing heterocylic compound or salt thereof FUJIFILM CORP 2015-09-09 CN disclosed
CN-102083427-B Inhibitors of carbonic anhydrase IX MOLECULAR INSIGHT PHARM INC 2014-12-10 CN disclosed
CN-102186847-A novel 2-amido thiadiazole derivatives ALMIRALL SA 2011-09-14 CN disclosed
CN-102083427-A Inhibitors of carbonic anhydrase IX MOLECULAR INSIGHT PHARM INC 2011-06-01 CN disclosed
CN-101437513-A Use of imidazo [2, 1-b ] -1, 3, 4-thiadiazole-2-sulfonamide compounds for the treatment of neuropathic pain AEGERA THERAPEUTICS INC (CA) 2009-05-20 CN disclosed
WO-2007062198-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECHNOLOGY, INC. (US) 2007-05-31 WO disclosed
EP-1252178-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-10-30 EP disclosed
WO-2001040262-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-07 WO disclosed
WO-1996017942-A9 PRODUCTION OF PEPTIDES USING RECOMBINANT FUSION PROTEIN CONSTRUCTS 1996-08-15 WO disclosed